Display options
Cite
Ewoldt TMJ, Abdulla A, Hunfeld NGM, et al. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022;44(1):224-229doi: 10.1097/FTD.0000000000000891.
Ewoldt, T. M. J., Abdulla, A., Hunfeld, N. G. M., Muller, A. E., Gommers, D., Polinder, S., Koch, B. C. P., & Endeman, H. (2022). Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Therapeutic drug monitoring, 44(1), 224-229. https://doi.org/10.1097/FTD.0000000000000891
Ewoldt, Tim M J, et al. "Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study." Therapeutic drug monitoring vol. 44,1 (2022): 224-229. doi: https://doi.org/10.1097/FTD.0000000000000891
Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891. PMID: 33770020; PMCID: PMC8746885.
Copy Download .nbib Format: NLM
Share it on

Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891.

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study.

Therapeutic drug monitoring

Tim M J Ewoldt, Alan Abdulla, Nicole G M Hunfeld, Anouk E Muller, Diederik Gommers, Suzanne Polinder, Birgit C P Koch, Henrik Endeman

Affiliations

  1. Departments of Intensive Care.
  2. Hospital Pharmacy, and.
  3. Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
  4. Department of Medical Microbiology, Haaglanden Medical Center, The Hague, the Netherlands; and.
  5. Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.

PMID: 33770020 PMCID: PMC8746885 DOI: 10.1097/FTD.0000000000000891

Abstract

BACKGROUND: Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is a cost determinant in the ICU.

METHODS: Patients included in the EXPAT trial were divided into target attainment and target nonattainment based on serum antibiotic levels. All hospital costs were extracted from the hospital administration system and categorized.

RESULTS: In total, 79 patients were included in the analysis. Target attainment showed a trend toward higher total ICU costs (€44,600 versus €28,200, P = 0.103). This trend disappeared when correcting for ICU length of stay (€2680 versus €2700). Renal replacement therapy was the most important cost driver.

CONCLUSIONS: Target attainment for beta-lactam antibiotics shows a trend toward higher total costs in ICU patients, which can be attributed to the high costs of a long stay in the ICU and renal replacement therapy.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. PLoS One. 2013 Oct 18;8(10):e77169 - PubMed
  2. Crit Care Res Pract. 2018 Sep 2;2018:5452683 - PubMed
  3. BMC Infect Dis. 2020 Jan 17;20(1):57 - PubMed
  4. Res Social Adm Pharm. 2020 Sep;16(9):1285-1289 - PubMed
  5. J Intensive Care Med. 2008 Jul-Aug;23(4):250-7 - PubMed
  6. J Hosp Infect. 2019 Feb;101(2):120-128 - PubMed
  7. Value Health. 2012 Jan;15(1):81-6 - PubMed
  8. Intensive Crit Care Nurs. 2016 Aug;35:66-73 - PubMed
  9. Ther Drug Monit. 2005 Feb;27(1):10-7 - PubMed
  10. Clin Infect Dis. 2014 Apr;58(8):1072-83 - PubMed
  11. Intensive Care Med. 2006 Apr;32(4):545-52 - PubMed
  12. Semin Respir Crit Care Med. 2015 Feb;36(1):136-53 - PubMed
  13. Int J Antimicrob Agents. 2008 Apr;31(4):345-51 - PubMed
  14. Crit Care. 2020 Sep 15;24(1):558 - PubMed
  15. Crit Care Clin. 2012 Jan;28(1):39-55, vi - PubMed
  16. Crit Care. 2007;11(3):R69 - PubMed
  17. Intensive Care Med. 2018 Jun;44(6):925-928 - PubMed
  18. Clinicoecon Outcomes Res. 2019 Aug 02;11:505-513 - PubMed
  19. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2171-2175 - PubMed
  20. JAMA. 2009 Dec 2;302(21):2323-9 - PubMed
  21. Drugs. 2018 Mar;78(4):439-451 - PubMed
  22. Intensive Care Med. 2009 Dec;35(12):2135-40 - PubMed
  23. J Crit Care. 2019 Aug;52:75-79 - PubMed
  24. Crit Care Resusc. 2019 Mar;21(1):63-68 - PubMed

Publication Types